Nakazato M, Kangawa K, Kurihara T, Matsukura S, Matsuo H
J Neurol Sci. 1987 Jun;79(1-2):111-6. doi: 10.1016/0022-510x(87)90265-6.
Structurally abnormal transthyretin is a precursor protein of amyloid fibrils in type I familial amyloidotic polyneuropathy (FAP). This variant transthyretin has an amino acid substitution of methionine for valine at position 30. The purpose of this study was to clarify whether this variant transthyretin also circulates in the cerebrospinal fluid (CSF) of patients with type I FAP. CSF transthyretin of the patients was purified and its primary structure determined. Sequence determination indicated that transthyretin consisted of a mixture of normal and variant transthyretin. Variant transthyretin was present in the CSF of all 5 Japanese FAP patients studied. The CSF concentration of variant transthyretin was high (0.72 +/- 0.15 mg/dl, mean +/- S.D.), suggesting that variant transthyretin is synthesized in the choroid plexus. Variant transthyretin was not present in any of 20 controls. The CSF concentration of total transthyretin in FAP patients was 1.74 +/- 0.42 mg/dl, which was not significantly different from controls.
结构异常的转甲状腺素蛋白是I型家族性淀粉样多神经病(FAP)中淀粉样原纤维的前体蛋白。这种变异的转甲状腺素蛋白在第30位氨基酸处缬氨酸被甲硫氨酸取代。本研究的目的是阐明这种变异的转甲状腺素蛋白是否也在I型FAP患者的脑脊液(CSF)中循环。对患者的脑脊液转甲状腺素蛋白进行了纯化并确定了其一级结构。序列测定表明,转甲状腺素蛋白由正常和变异转甲状腺素蛋白混合组成。在所研究的所有5例日本FAP患者的脑脊液中均存在变异转甲状腺素蛋白。变异转甲状腺素蛋白的脑脊液浓度较高(0.72±0.15mg/dl,均值±标准差),提示变异转甲状腺素蛋白是在脉络丛中合成的。20例对照中均未检测到变异转甲状腺素蛋白。FAP患者脑脊液中转甲状腺素蛋白的总浓度为1.74±0.42mg/dl,与对照组无显著差异。